BiomX Inc. (PHGE)
Company Description
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria.
It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials.
The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S.
aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment.
BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Country | Israel |
Founded | 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 54 |
CEO | Jonathan Eitan Solomon MBA |
Contact Details
Address: 22 Einstein St., 4th Floor Ness Ziona, L3 7414003 Israel | |
Phone | (972) 72 394 2377 |
Website | biomx.com |
Stock Details
Ticker Symbol | PHGE |
Exchange | NYSEAMERICAN |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001739174 |
CUSIP Number | 09090D103 |
ISIN Number | US09090D1037 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Jonathan Eitan Solomon MBA | Chief Executive Officer and Director |
Marina Wolfson CPA | Chief Financial Officer and Secretary |
Dr. Merav Bassan Ph.D. | Chief Development Officer |
Prof. Rotem Sorek Ph.D. | Scientific Founder |
Dr. Eran Elinav M.D., Ph.D. | Scientific Founder |
Dr. Timothy K. Lu M.D., Ph.D. | Scientific Founder |
Inbal Benjamini-Elran | C.H.R.O |
Assaf Oron | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Mar 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Mar 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
Mar 21, 2024 | 8-K/A | [Amend] Current report |
Mar 19, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Mar 18, 2024 | 8-K | Current Report |
Mar 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Mar 6, 2024 | 8-K | Current Report |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |